<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ondine Biomedical Inc — News on 6ix</title>
<link>https://6ix.com/company/ondine-biomedical-inc</link>
<description>Latest news and press releases for Ondine Biomedical Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ondine-biomedical-inc" rel="self" type="application/rss+xml" />
<item>
<title>ICU Study to be Presented at 2026 CACCN Conference</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/icu-study-to-be-presented-at-2026-caccn-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/icu-study-to-be-presented-at-2026-caccn-conference</guid>
<pubDate>Mon, 27 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that findings from its Steriwave ICU study, demonstrating a 39.5% reduction in pneumonia rates and significant pathogen reduction with no adverse events, have been selected for oral and poster presentation at the Canadian Critical Care Nursing Conference. This study, the first deployment of nasal photodisinfection in an ICU setting, highlights the non-antibiotic Steriwave therapy's potential to reduce healthcare-associated infections and address antimicrobial res</description>
</item>
<item>
<title>Marked Reduction in SSIs at Ottawa Heart Institute</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/marked-reduction-in-ssis-at-ottawa-heart-institute</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/marked-reduction-in-ssis-at-ottawa-heart-institute</guid>
<pubDate>Thu, 23 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that the University of Ottawa Heart Institute observed a statistically significant reduction in surgical site infections among cardiac surgery patients after implementing Steriwave nasal decolonisation into their presurgical protocols, comparing an eight-month pilot program with Steriwave against a prior 24-month control period using mupirocin. These positive findings, which are expected to be presented at a major international cardiac conference and detailed in </description>
</item>
<item>
<title>Two Abstracts Accepted at World Congress</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/two-abstracts-accepted-at-world-congress</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/two-abstracts-accepted-at-world-congress</guid>
<pubDate>Wed, 22 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that two abstracts have been accepted for presentation at the 2026 World Congress on Infectious Diseases, highlighting eight-year longitudinal data on its light-activated antimicrobial technology. One abstract details a 66% reduction in Surgical Site Infections (SSIs) and sustained cost savings in spine surgery without resistance signals, while the second addresses limitations in infection control reporting. The company's CEO emphasized the sustained SSI reductio</description>
</item>
<item>
<title>Steriwave ICU Study Shows 39.5% Pneumonia Drop</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/steriwave-icu-study-shows-395percent-pneumonia-drop</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/steriwave-icu-study-shows-395percent-pneumonia-drop</guid>
<pubDate>Tue, 14 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that a peer-reviewed study published in Critical Care, conducted by the Royal Columbian Hospital Foundation, demonstrated a 39.5% reduction in pneumonia rates in ICU patients treated with Steriwave® nasal photodisinfection therapy, decreasing from 14.9 to 9.0 cases per 1000 ICU patient-days. While not powered for statistical significance on this outcome, the reduction was associated with a statistically significant decrease in early cumulative nasal pathogen burd</description>
</item>
<item>
<title>Business Update</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/business-update-129</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/business-update-129</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. reported a 29% unaudited revenue growth in 2025 and has completed patient enrollment in its pivotal LANTERN Phase 3 U.S. trial, with results anticipated in Spring 2026. The company is expanding its real-world evidence through SSI reduction programs and has initiated in-house manufacturing upgrades to support future growth and enhance supply chain control. Significant investments in facility upgrades and automation equipment are underway to improve operational efficacy and </description>
</item>
<item>
<title>ICU Study Accepted for Publication</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/icu-study-accepted-for-publication</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/icu-study-accepted-for-publication</guid>
<pubDate>Wed, 08 Apr 2026 06:08:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced a significant research milestone as its pilot study evaluating nasal photodisinfection in an intensive care unit setting has been accepted for publication in the Journal of Critical Care. This study, titled "Suppression of Microbial Burden to Reduce Pneumonia in Critical Illness: the SMURF Feasibility Pilot Study," marks the first-ever deployment of this non-antibiotic therapy in critically ill patients, extending its application beyond surgical settings and cont</description>
</item>
<item>
<title>Holdings in Company</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/holdings-in-company-1027</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/holdings-in-company-1027</guid>
<pubDate>Tue, 24 Mar 2026 16:28:00 GMT</pubDate>
<description>M&G Plc has increased its holding in Ondine Biomedical Inc. to 14.29% of the voting rights, crossing a 1% threshold. This change, effective March 16, 2026, represents a total of 74,268,775 voting rights. The previous notification showed a holding of 13.04%. The notification was made on March 17, 2026, and the increase is due to movements within M&G Plc's controlled undertakings.
Disclaimer*</description>
</item>
<item>
<title>Ondine Provides Update on US Phase 3 Pivotal Study</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/ondine-provides-update-on-us-phase-3-pivotal-study</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/ondine-provides-update-on-us-phase-3-pivotal-study</guid>
<pubDate>Tue, 10 Mar 2026 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. has provided an update on its LANTERN Phase 3 pivotal study, confirming it remains on track to report top-line results in Spring 2026. With 93% of patients enrolled across 14 HCA Healthcare hospitals and four major Canadian centres, the study shows strong progress, with over 92% of clinical report forms complete and 80% of monitoring visits finalized. Participant retention exceeds 98%, and nearly 80% of primary endpoint adjudications are complete, indicating robust data in</description>
</item>
<item>
<title>Share Issuance for ICU Study Submission</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/share-issuance-for-icu-study-submission</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/share-issuance-for-icu-study-submission</guid>
<pubDate>Wed, 25 Feb 2026 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. has issued 1,184,504 new common shares at 9.75 pence each, representing the final milestone payment for its Steriwave® ICU pilot study at Royal Columbian Hospital, which concluded with the submission of study results for publication. This share issuance, equivalent to 25% of the C$855,000 total study cost, allows Ondine to preserve cash while advancing its technology into critical care settings, potentially accessing an additional C$4 billion addressable market. The new sh</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/holdings-in-company-1028</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/holdings-in-company-1028</guid>
<pubDate>Fri, 20 Feb 2026 17:40:00 GMT</pubDate>
<description>M&G Plc has notified Ondine Biomedical Inc. of a movement in its major holding, crossing a threshold on February 11, 2026. The total voting rights held by M&G Plc now stand at 13.041900%, representing 67,604,901 voting rights attached to shares, an increase from its previous notification of 12.974380%. This change is attributed to a movement of 1% as per the company's articles.
Disclaimer*</description>
</item>
<item>
<title>Ondine and Mid Yorks Win National Award</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/ondine-and-mid-yorks-win-national-award</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/ondine-and-mid-yorks-win-national-award</guid>
<pubDate>Fri, 06 Feb 2026 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust have received the Excellence in Healthcare Partnership Award for their collaboration utilizing Ondine's Steriwave® nasal photodisinfection technology, which demonstrated a 71% reduction in post-surgical infections for hip surgery and no observed infections in knee surgery. This partnership highlights the effectiveness of non-antibiotic innovations in combating surgical site infections and supporting NHS priorities, leading to broader ad</description>
</item>
<item>
<title>Steriwave Up for 2025 “Product of the Year” Award</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/steriwave-up-for-2025-product-of-the-year-award</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/steriwave-up-for-2025-product-of-the-year-award</guid>
<pubDate>Mon, 02 Feb 2026 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. has announced that its Steriwave® nasal photodisinfection technology has been selected as a finalist for the 2025 Bionow Product of the Year Award, a significant recognition given a 50% increase in nominations this year. This non-antibiotic antimicrobial process, which eliminates nasal pathogens to prevent surgical site infections, has seen growing adoption in the UK healthcare landscape, with clinical partnerships at Mid Yorkshire Teaching NHS Trust and NHS Guy's and St. </description>
</item>
<item>
<title>Expanding Steriwave Use Across Vancouver Island</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/expanding-steriwave-use-across-vancouver-island</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/expanding-steriwave-use-across-vancouver-island</guid>
<pubDate>Tue, 27 Jan 2026 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that Cowichan District Hospital, part of Island Health, will adopt its Steriwave nasal photodisinfection technology for orthopedic patients, aiming to prevent surgical site infections. This adoption coincides with the hospital's significant CAD$1.4 billion expansion, which will nearly double its operating rooms to seven, positioning it as a hub for complex orthopedic surgeries. Steriwave, a five-minute light-activated process, eliminates nasal pathogens without c</description>
</item>
<item>
<title>Steriwave Expands into ENT Surgery in Spain</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/steriwave-expands-into-ent-surgery-in-spain</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/steriwave-expands-into-ent-surgery-in-spain</guid>
<pubDate>Thu, 22 Jan 2026 09:42:00 GMT</pubDate>
<description>Ondine Biomedical Inc. has announced the expansion of its Steriwave nasal photodisinfection technology into ENT surgery centres in Spain, targeting procedures like septoplasty, sinuplasty, and functional endoscopic sinus surgery, which represent a significant growth area with approximately 600,000 annual procedures in the USA, including over 300,000 for Chronic Rhinosinusitis. This non-invasive, five-minute treatment effectively destroys bacteria, viruses, and fungi, including antibiotic-resista</description>
</item>
<item>
<title>New Independent Study Supports Photodisinfection</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/new-independent-study-supports-photodisinfection</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/new-independent-study-supports-photodisinfection</guid>
<pubDate>Tue, 13 Jan 2026 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. highlights new research published in Nature Communications that supports its photodisinfection technology by providing biological context for nasal decolonization strategies. The CARRIAGE study, analyzing approximately 1,180 healthy adults, redefines Staphylococcus aureus colonization as a low-diversity microbial state that can fluctuate, suggesting limitations of traditional screening and antibiotic-based treatments which can disrupt beneficial bacteria. Clinical evaluati</description>
</item>
<item>
<title>Finalist for 2nd National Award for SSI reduction</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/finalist-for-2nd-national-award-for-ssi-reduction</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/finalist-for-2nd-national-award-for-ssi-reduction</guid>
<pubDate>Tue, 23 Dec 2025 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust have been shortlisted for the Excellence in Healthcare Partnership Award for their work in reducing surgical site infections using nasal photodisinfection technology. This partnership's Steriwave intervention demonstrated a 71% reduction in post-surgical infections in hip surgery and no observed infections in knee surgery over a six-month period at two hospitals, highlighting its potential for patient safety and cost savings within the </description>
</item>
<item>
<title>First German Hospital Pilots Steriwave</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/first-german-hospital-pilots-steriwave</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/first-german-hospital-pilots-steriwave</guid>
<pubDate>Mon, 22 Dec 2025 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. has announced a significant research collaboration with LMU University Hospital Munich to pilot its Steriwave photodisinfection technology in Germany, marking a key step for international market expansion. This partnership leverages the expertise of LMU's LIFE Center and builds on previous clinical evidence, including a pilot study that showed a substantial reduction in post-operative antibiotic prescriptions from 22.5% to 5% in sinonasal surgery patients. The company aims</description>
</item>
<item>
<title>Ondine shortlisted for HSJ Partnership Award</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/ondine-shortlisted-for-hsj-partnership-award</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/ondine-shortlisted-for-hsj-partnership-award</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. has been shortlisted for a prestigious HSJ Partnership Award alongside Mid Yorkshire Teaching NHS Trust for their work in reducing post-surgical infection rates with Ondine's Steriwave® technology. This collaboration demonstrated a 71% reduction in surgical site infections over six months, with independent analysis by the York Health Economics Consortium estimating potential annual savings of up to £200 million across UK hospitals, as Steriwave offers an antibiotic-sparing</description>
</item>
<item>
<title>Topline Results Significant in Steriwave ICU Study</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/topline-results-significant-in-steriwave-icu-study</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/topline-results-significant-in-steriwave-icu-study</guid>
<pubDate>Mon, 27 Oct 2025 07:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced positive preliminary results from its Steriwave ICU Pilot Study at Royal Columbian Hospital, demonstrating a significant reduction in harmful pathogens in ICU patients. The study, involving 249 critically ill patients, showed a significant reduction in nasal bacterial load (p < 0.05) in the Steriwave group compared to the control. By day 8, the share of swabs positive for opportunistic pathogens was 4.5% in the treatment group versus 22.4% in the control group, r</description>
</item>
<item>
<title>Cambridge’s Papworth Hospital Pilots Steriwave</title>
<link>https://6ix.com/company/ondine-biomedical-inc/news/cambridges-papworth-hospital-pilots-steriwave</link>
<guid isPermaLink="true">https://6ix.com/company/ondine-biomedical-inc/news/cambridges-papworth-hospital-pilots-steriwave</guid>
<pubDate>Thu, 02 Oct 2025 06:00:00 GMT</pubDate>
<description>Ondine Biomedical Inc. announced that Royal Papworth Hospital NHS Foundation Trust is piloting Steriwave nasal photodisinfection therapy to improve patient safety during complex cardiac surgeries. This initiative, developed with Mölnlycke Health Care, aims to reduce surgical site infections (SSIs) amidst rising antimicrobial resistance (AMR). A previous study at Canada's Mazankowski Alberta Heart Institute showed a 32% reduction in cardiac SSIs using a similar protocol compared to mupirocin. Ste</description>
</item>
</channel>
</rss>